ArticleNeuropsychiatric disease and treatment2008
Pregabalin for the management of partial epilepsy.
Article in Neuropsychiatric disease and treatment, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 3 syntheses or guidelines pooled it, 38 citations in OpenAlex.
- Pregabalin add-on for drug-resistant focal epilepsy.The Cochrane database of systematic reviews · 2022Pooled it
- Pregabalin add-on for drug-resistant focal epilepsy.The Cochrane database of systematic reviews · 2019Pooled it
- The efficacy of pregabalin for the management of postoperative pain in primary total knee and hip arthroplasty: a meta-analysis.Journal of orthopaedic surgery and research · 2017Pooled it
- The anxiolytic effects of preoperative administration of pregabalin in comparison to diazepam and placebo.Scientific reports · 2023Trial
- Comparative Study of the Neurotoxic Effects of Pregabalin Versus Tramadol in Rats.Neurotoxicity research · 2022Article
- Effects of Pregabalin, Nimodipine, and Their Combination in the Inhibition of Status Epilepticus and the Prevention of Death in MiceTurkish journal of pharmaceutical sciences · 2021Article
- Gabapentinoids: pharmacokinetics, pharmacodynamics and considerations for clinical practice.British journal of pain · 2020Article
- Synergistic anticonvulsant effects of pregabalin and amlodipine on acute seizure model of epilepsy in mice.Metabolic brain disease · 2017Article
- Antiepileptic drugs in development pipeline: A recent update.eNeurologicalSci · 2016Review
- Efficacy of pregabalin in childhood refractory partial seizure.Iranian journal of pediatrics · 2014Article
- Pregabalin in the management of partial epilepsy.Neuropsychiatric disease and treatment · 2009Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Pregabalin is one of the latest antiepileptic drugs introduced for the treatment of partial epilepsy. Its efficacy and safety as adjunctive therapy in refractory partial epilepsy have been established in four double-blind placebo-controlled trials (n = 1396) and 4 long-term open-label studies (n = 1480). In 3 fixed-dose trials, the proportion of patients with a >/=50% reduction in seizure frequency across the effective dose-range (150-600 mg/day) ranged between 14% and 51%, with a clear dose-response relationship. Suppression of seizure activity could be demonstrated as early as day 2. The most frequently reported CNS-related adverse events included dizziness, somnolence, ataxia and fatigue, were usually mild or moderate, and tended to be dose related. In long-term studies, weight gain was reported as an adverse event by 24% of patients. When pregabalin dose was individualized to according to response within the 150 to 600 mg/day dose range, tolerability was considerably improved compared with use of a high-dose, fixed-dose regimen (600 mg/day) without titration. In long-term studies up to 4 years, no evidence of loss efficacy was identified. During the last year on pregabalin, 3.7% of patients were seizure-free. Pregabalin appears to be a useful addition to the therapeutic armamentariun for the management of refractory partial epilepsy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.